COVID-19 Immunity Assessment

DxTerity

Status

Completed

Conditions

COVID-19

Study type

Observational

Funder types

Industry

Identifiers

NCT05080231

PROT-0239

Details and patient eligibility

About

The purpose of this study is to collect blood specimens from individuals post infection or post vaccination over time to assess COVID19 Immunity.

Full description

The DxTerity COVID-19 Immunity Assessment Collection Mailer Kit contains the DxCollect MicroCollection Device (MCD) Serology fingerstick blood collection device packaged as a home collection kit, designed for collection and shipment of fingerstick blood back to DxTerity CLIA (Clinical Laboratory Improvements Amendment) certified laboratory for testing.

The clinical performance of the collection device for use with anti-SARS-CoV-2 antibody tests will be evaluated for use with cPASS™ anti-SARS-CoV-2 neutralizing antibody detection kit (EUA 201427).

The samples may also be used for assessing immunity or protection post COVID-19 vaccination.

Enrollment

662 patients

Sex

All

Ages

13+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Males and females ≥13 years old.
Not vaccinated and were previously positive for COVID-19 OR are vaccinated for COVID-19.
Provides test report to demonstrate prior COVID-19 positive result (only applicable to unvaccinated subjects who were previously positive for COVID-19, not applicable for COVID-19 vaccinated subjects).
Provides informed consent and completed questionnaire.
Able to register the collection kit on the DxTerity portal.
Able to collect and ship blood samples back to DxTerity.

Exclusion criteria

Unable to provide COVID-19 positive test report (only applicable to unvaccinated subjects who were previously positive for COVID-19, not applicable for COVID-19 vaccinated subjects).
Unable to complete informed consent and/or questionnaire.
Unable to complete the study activities in a timely manner.